{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:19:59Z","timestamp":1784107199265,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.yrtph.2022.105224","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T00:02:47Z","timestamp":1657324967000},"page":"105224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The utility of hERG channel inhibition data in the derivation of occupational exposure limits"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4535-3486","authenticated-orcid":false,"given":"Jillian A.","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest S.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Trejo-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suren","family":"Bandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Bercu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2022.105224_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.chs.2005.01.016","article-title":"Occupational health categorization and compound handling practice systems\u2014roots, application and future","volume":"12","author":"Ader","year":"2005","journal-title":"Chem. Health Saf."},{"issue":"2","key":"10.1016\/j.yrtph.2022.105224_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1359-6446(04)03278-7","article-title":"Predictive in silico modeling for hERG channel blockers","volume":"10","author":"Aronov","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.yrtph.2022.105224_bib3","series-title":"Draft Guidance for Industry: E14 and S7B Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential - Questions and Answers","year":"2020"},{"key":"10.1016\/j.yrtph.2022.105224_bib4","article-title":"In silico approaches in organ toxicity hazard assessment: current status and future needs for predicting heart, kidney and lung toxicities","volume":"20","author":"Bassan","year":"2021","journal-title":"Comput. Toxicol."},{"issue":"Suppl. 1","key":"10.1016\/j.yrtph.2022.105224_bib5","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.yrtph.2016.05.028","article-title":"Point of departure (PoD) selection for the derivation of acceptable daily exposures (ADEs) for active pharmaceutical ingredients (APIs)","volume":"79","author":"Bercu","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105224_bib6","series-title":"About CiPA","author":"CiPA","year":"2022"},{"issue":"5","key":"10.1016\/j.yrtph.2022.105224_bib7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cmdc.201000024","article-title":"Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases","volume":"5","author":"Doddareddy","year":"2010","journal-title":"ChemMedChem"},{"issue":"Suppl. 1","key":"10.1016\/j.yrtph.2022.105224_bib8","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.yrtph.2016.05.026","article-title":"Using default methodologies to derive an acceptable daily exposure (ADE)","volume":"79","author":"Faria","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105224_bib9","series-title":"Derek Nexus HERG QMRF","author":"Fisk","year":"2020"},{"issue":"4","key":"10.1016\/j.yrtph.2022.105224_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/apb.2021.0004","article-title":"Occupational exposure risks when working with protein therapeutics and the development of a biologics banding system","volume":"26","author":"Graham","year":"2021","journal-title":"Appl. Biosaf."},{"key":"10.1016\/j.yrtph.2022.105224_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pharmthera.2008.05.009","article-title":"The hERG potassium channel and hERG screening for drug-induced torsades de pointes","volume":"119","author":"Hancox","year":"2008","journal-title":"Pharmacol. Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.yrtph.2022.105224_bib12","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.yrtph.2016.06.001","article-title":"A harmonization effort for acceptable daily exposure application to pharmaceutical manufacturing - operational considerations","volume":"79","author":"Hayes","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105224_bib13","series-title":"S7A: Safety Pharmacology Studies for Human Pharmaceuticals - Step 5. CPMP\/ICH\/539\/00","year":"2000"},{"key":"10.1016\/j.yrtph.2022.105224_bib14","series-title":"S7B: the Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals - Step 5. CPMP\/ICH\/423\/02","year":"2005"},{"key":"10.1016\/j.yrtph.2022.105224_bib15","series-title":"E14: the Clinical Evlauation of QT\/QTs Interval Prolongation and Proarrhythmic Poential for Non-antiarrhythmic Drugs - Step 5. CHMP\/IC\/2\/04","year":"2005"},{"issue":"5","key":"10.1016\/j.yrtph.2022.105224_bib16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4155\/fmc.15.18","article-title":"In silico prediction of hERG inhibition","volume":"7","author":"Jing","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.yrtph.2022.105224_bib17","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1124\/mol.105.020990","article-title":"Molecular determinants of HERG channel block","volume":"69","author":"Kamiya","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105224_bib18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1039\/C7NP00014F","article-title":"Natural products modulating the hERG channel: heartaches and hope","volume":"34","author":"Kratz","year":"2017","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.yrtph.2022.105224_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0009-8981(85)90082-8","article-title":"Free drug measurements: methodology and clinical significance","volume":"151","author":"Kwong","year":"1985","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.yrtph.2022.105224_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1476-5381.2011.01255.x","article-title":"How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?","volume":"163","author":"Laverty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105224_bib21","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1161\/CIRCULATIONAHA.118.035455","article-title":"Modernized classification of cardiac antiarrhythmic drugs","volume":"138","author":"Lei","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.yrtph.2022.105224_bib22","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/FJC.0b013e3181d2ce39","article-title":"Protein binding-dependent decreases in hERG channel blocker potency assessed by whole-cell voltage clamp in serum","volume":"55","author":"Margulis","year":"2010","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105224_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.bjp.0705336","article-title":"Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine","volume":"139","author":"Mitcheson","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105224_bib24","doi-asserted-by":"crossref","first-page":"12329","DOI":"10.1073\/pnas.210244497","article-title":"A structural basis for drug-induced long QT syndrome","volume":"97","author":"Mitcheson","year":"2000","journal-title":"PNAS"},{"key":"10.1016\/j.yrtph.2022.105224_bib25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1085\/jgp.115.3.229","article-title":"Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate","volume":"115","author":"Mitcheson","year":"2000","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.yrtph.2022.105224_bib26","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3389\/fphar.2018.01035","article-title":"Experimentally validated pharmacoinformatics approach to predict hERG inhibition potential of new chemical entities","volume":"9","author":"Munawar","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105224_bib27","series-title":"Technical Report: the NIOSH Occupational Exposure Banding Process for Chemical Risk Management. By Lentz TJ, Seaton M, Rane P, Gilbert SJ, McKernan LT, Whittaker C","year":"2019"},{"key":"10.1016\/j.yrtph.2022.105224_bib28","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1006\/bbrc.2001.4269","article-title":"Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide","volume":"280","author":"Paul","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yrtph.2022.105224_bib29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/mol.104.000117","article-title":"Structural determinants of HERG channel block by clofilium and ibutilide","volume":"66","author":"Perry","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105224_bib30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/978-1-0716-1960-5_17","article-title":"Use of lhasa limited products for the in silico prediction of drug toxicity","volume":"2425","author":"Ponting","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.yrtph.2022.105224_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4161\/chan.2.2.6004","article-title":"Role of hERG potassium channel assays in drug development","volume":"2","author":"Priest","year":"2008","journal-title":"Channels"},{"key":"10.1016\/j.yrtph.2022.105224_bib32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.bjp.0706892","article-title":"Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine","volume":"149","author":"Rajamani","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105224_bib33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.yrtph.2022.105224_bib34","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.bbrc.2004.10.127","article-title":"High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656","volume":"325","author":"Ridley","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yrtph.2022.105224_bib35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.yrtph.2022.105224_bib36","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0026-895X(25)09019-4","article-title":"High affinity open channel block by dofetilide of HERG expressed in a human cell line","volume":"49","author":"Snyders","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.yrtph.2022.105224_bib37","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1124\/jpet.300.2.543","article-title":"The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (hERG) potassium channels","volume":"300","author":"Thomas","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.yrtph.2022.105224_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/toxsci\/kfac013","article-title":"The challenges of predicitng drug-induced QTc prolongation in humans","volume":"187","author":"Valentin","year":"2022","journal-title":"Toxicol. Sci."},{"issue":"16","key":"10.1016\/j.yrtph.2022.105224_bib39","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1111\/bph.13207","article-title":"Evaluation of drug\u2010induced QT interval prolongation in animal and human studies: a literature review of concordance","volume":"172","author":"Vargas","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.yrtph.2022.105224_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: a pharma industry perspective","volume":"109","author":"Vargas","year":"2021","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"6","key":"10.1016\/j.yrtph.2022.105224_bib41","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.jelectrocard.2018.08.003","article-title":"Update on the ECG component of the CiPA initiative","volume":"51","author":"Vincente","year":"2018","journal-title":"J. Electrocardiol."},{"key":"10.1016\/j.yrtph.2022.105224_bib42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/toxsci\/kfy270","article-title":"Today's challenges to de-risk and predict drug safety in human \"Mind-the-Gap","volume":"167","author":"Weaver","year":"2019","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2022.105224_bib43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1517\/14728222.11.3.321","article-title":"The hERG potassium channel as a therapeutic target","volume":"11","author":"Witchel","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.yrtph.2022.105224_bib44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.taap.2013.10.024","article-title":"Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs","volume":"274","author":"Yu","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230022001118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230022001118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:34:12Z","timestamp":1759494852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230022001118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":44,"alternative-id":["S0273230022001118"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2022.105224","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The utility of hERG channel inhibition data in the derivation of occupational exposure limits","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2022.105224","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105224"}}